Mp67-18 clinical Characteristics of Prostate Cancer Patients in West and South Africa in the Men of African Descent and Carcinoma of the Prostate (Madcap) Consortium Study

Jalloh, Mohamed; Zhu, Denzel; Agalliu, Ilir; Andrews, Caroline; Kovac, Evan; Adusei, Ben; Snyper, Nana Yaa; Mensah, James E.; Okyne, Victoria; Hsing, Ann W.; Adebiyi, Akindele Olupelumi; Ogunbiyi, Olufemi; Shittu, O B; Olabode, Peter Oluwole; Nwegbu, Maxwell M.; Aisuodionoe-Shadrach, Oseremen I.; Fernandez, P.; Irusen, Hayley; Pentz, Audrey; Joffe, Maureen; Singh, Elvira; Jacobson, Judith S.; Neugut, Alfred I.; Rohan, Thomas E.; Niang, Lamine; Guèye, Serigne; Rebbeck, Timothy R.

doi:10.1097/ju.0000000000002028.18

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent reports from the Men of African Descent and Carcinoma of the Prostate (MADCaP) Consortium Study of 2588 men with PCa in west Africa showed that the majority of men (78.9%) had high D'Amico-risk PCa [19]. Because most countries from LMICs lack guidelines on screening and early diagnosis, efforts should be made to develop best practice in PCa diagnosis and management in LMICs.…”

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Global viewpoints: updates on prostate cancer in Sub‐Saharan Africa

Jalloh,

Cassell,

Niang

et al. 2023

BJU International

View full text Add to dashboard Cite

Prostate cancer (PCa) is a major health concern in Sub‐Saharan Africa (SSA), with high incidence and mortality rates. However, the widely used prostate‐specific antigen (PSA) screening is not readily available or affordable in SSA. Alternative screening strategies, such as risk stratification approaches and cost‐effective PSA tests, are being explored to target high‐risk individuals and improve access to screening. Diagnosis of PCa in SSA is challenging due to the lack of access to diagnostic tools and limited healthcare resources. Clinical evaluation and digital rectal examination are commonly used, but PSA testing, magnetic resonance imaging, and biopsy are often limited. As a result, many men in SSA are diagnosed at advanced stages of the disease. Treatment options for PCa in SSA are often limited by a lack of resources and trained healthcare providers. Surgery, radiation therapy, and androgen‐deprivation therapy are available but may be inaccessible to many patients. Cultural beliefs and stigma surrounding PCa further impact treatment decisions. Improved patient and community awareness, electronic medical records, and communication between patients and healthcare professionals can enhance evidence‐based decision‐making and advocate for policy changes. Understanding the genetic determinants and implementing comprehensive strategies can lead to improved outcomes and better control of PCa in SSA.

show abstract

Section: Diagnosismentioning

confidence: 99%

“…Results from the MADCaP study also showed that most men in SSA with PCa presented with moderate to severe LUTS (Table 1) [19]. As such, clinically invasive disease (Stage T3b) was more prevalent in west African men compared to men in South Africa (64.5% vs 20.2%, P < 0.001) [19].…”

Section: Introductionmentioning

confidence: 99%